State of anticoagulant and fibrinolytic systems of blood in patients with hypertension in combination with non-alcoholic fatty liver disease

Authors

  • Nataliia Bazhenova Bogomolets National Medical University T. Shevchenka blvd., 13, Kyiv, Ukraine, 01601 Kyiv Railway Clinical Hospital No. 2 of branch "Health center" of the Public Joint Stock Company "Ukrainian Railway" Povitroflotskyi ave., 9, Kyiv, Ukraine, 01049, Ukraine https://orcid.org/0000-0002-5640-4317

DOI:

https://doi.org/10.15587/2519-4798.2018.147805

Keywords:

hypertension, non-alcoholic fatty liver disease, anticoagulant, blood fibrinolytic activity

Abstract

Aim of the research. To determine the state of the anticoagulant and fibrinolytic activity of blood in patients with hypertension and concomitant non-alcoholic fatty liver disease.

Methods. 132 patients were examined. 45 patients with hypertension stage II (HT) with concomitant non-alcoholic fatty liver disease (NAFLD), 31 patients with NAFLD without HT, 41 patients with HT without concomitant NAFLD. The control group - 15 healthy individuals of comparable age and sex. To achieve the aim the study of the anticoagulant and fibrinolytic link was carried out by special laboratory studies.

Results. When compared with the control group, the level of Antithrombin III decreased by 16.4 % in the HT group (p<0.01) and in the NAFLD group (p<0.01), HT+NAFLD – by 20.3 % (p<0.001). The level of Protein C in patients with hypertension decreased by 26 % (p<0.001), with NAFLD – by 9.5 % (p<0.05), with NAFLD+HT – by 14.1 % (p<0.01). Plasminogen decreased in HT – by 15 % (p<0.001), NAFLD – by 20.9 % (p<0.001), NAFLD+HT – by 16.5 % (p<0.001). The duration of Hageman-dependent fibrinolysis is increased in all groups compared to control: in the HT group – by 47 % (p<0.001), in the NAFLD group – by 78 % (p<0.001), in the NAFLD+HT group – 2.4 times (p<0.001).

Conclusions. Suppression of anticoagulant hemostasis is observed in patients with hypertension and with NAFLD. The decrease in the fibrinolytic activity of the blood system is reflected in the extension of the dissolution time of the fibrin clot in the group of patients with hypertension, NAFLD, NAFLD combined with HT. The level of plasminogen decreased to the same extent in patients with hypertension and with the combination of hypertension and NAFLD but isolated NAFLD had a stronger effect on this indicator. NAFLD is a risk factor for thrombophilic changes in the blood

Author Biography

Nataliia Bazhenova, Bogomolets National Medical University T. Shevchenka blvd., 13, Kyiv, Ukraine, 01601 Kyiv Railway Clinical Hospital No. 2 of branch "Health center" of the Public Joint Stock Company "Ukrainian Railway" Povitroflotskyi ave., 9, Kyiv, Ukraine, 01049

Postgraduate student

Department of inernal medicine No. 1

Doctor

Admission daprtment

References

  1. Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M. et. al. (2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 39 (33), 3021–3104. doi: http://doi.org/10.1093/eurheartj/ehy339
  2. Gajalakshmi, V., Lacey, B., Kanimozhi, V., Sherliker, P., Peto, R., Lewington, S. (2018). Body-mass index, blood pressure, and cause-specific mortality in India: a prospective cohort study of 500 810 adults. The Lancet Global Health, 6 (7), e787–e794. doi: http://doi.org/10.1016/s2214-109x(18)30267-5
  3. Lewington, S., Clarke, R., Qizilbash, N., Peto, R., Collins, R. (2002). Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 360 (9349), 1903–1913. doi: http://doi.org/10.1016/s0140-6736(02)11911-8
  4. Momot, A. P. (2015). The problem of thrombophilia in clinical practice. Russian Journal of Children Hematology and Oncology, 2 (1), 36–48. doi: http://doi.org/10.17650/2311-1267-2015-1-36-48
  5. Lee, K. W., Lip, G. Y. H. (2003). Effects of Lifestyle on Hemostasis, Fibrinolysis, and Platelet Reactivity. Archives of Internal Medicine, 163 (19), 2368. doi: http://doi.org/10.1001/archinte.163.19.2368
  6. Junker, R., Heinrich, J., Schulte, H., Erren, M., Assmann, G. (1998). Hemostasis in normotensive and hypertensive men: results of the PROCAM study. The prospective cardiovascular Münster study. Journal of Hypertension, 16 (7), 917–923. doi: http://doi.org/10.1097/00004872-199816070-00004
  7. Woodward, M., Lowe, G. D., Rumley, A., Tunstall-Pedoe, H., Philippou, H., Lane, D. A., Morrison, C. E. (1997). Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. British Journal of Haematology, 97 (4), 785–797. doi: http://doi.org/10.1046/j.1365-2141.1997.1232935.x
  8. Makris, T. K., Tsoukala, C., Krespi, P., Hatzizacharias, A., Gialeraki, A., Papargyriou, J. et. al. (1997). Haemostasis balance disorders in patients with essential hypertension. Thrombosis Research, 88 (2), 99–107. doi: http://doi.org/10.1016/s0049-3848(97)00222-3
  9. Corseaux, D., Ollivier, V., Fontaine, V., Huisse, M.-G., Philippe, M., Louedec, L. et. al. (2002). Hemostasis imbalance in experimental hypertension. Molecular Medicine, 8 (4), 169–178. doi: http://doi.org/10.1007/bf03402009
  10. Rinella, M. E. (2015). Nonalcoholic Fatty Liver Disease. JAMA, 313 (22), 2263–2273. doi: http://doi.org/10.1001/jama.2015.5370
  11. Bril, F., Cusi, K. (2017). Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Diabetes Care, 40 (3), 419–430. doi: http://doi.org/10.2337/dc16-1787
  12. Byrne, C. D., Targher, G. (2015). NAFLD: A multisystem disease. Journal of Hepatology, 62 (1), S47–S64. doi: http://doi.org/10.1016/j.jhep.2014.12.012
  13. Fotbolcu, H., Zorlu, E. (2016). Nonalcoholic fatty liver disease as a multi-systemic disease. World Journal of Gastroenterology, 22 (16), 4079–4090. doi: http://doi.org/10.3748/wjg.v22.i16.4079
  14. Potze, W., Siddiqui, M. S., Boyett, S. L., Adelmeijer, J., Daita, K., Sanyal, A. J., Lisman, T. (2016). Preserved hemostatic status in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 65 (5), 980–987. doi: http://doi.org/10.1016/j.jhep.2016.06.001
  15. Kopec, A. K., Joshi, N., Luyendyk, J. P. (2016). Role of hemostatic factors in hepatic injury and disease: animal models de-liver. Journal of Thrombosis and Haemostasis, 14 (7), 1337–1349. doi: http://doi.org/10.1111/jth.13327
  16. Essalmani, R., Susan-Resiga, D., Guillemot, J., Kim, W., Sachan, V., Awan, Z. et. al. (2017). Thrombin activation of protein C requires prior processing by a liver proprotein convertase. Journal of Biological Chemistry, 292 (25), 10564–10573. doi: http://doi.org/10.1074/jbc.m116.770040
  17. Chapin, J. C., Hajjar, K. A. (2015). Fibrinolysis and the control of blood coagulation. Blood Reviews, 29 (1), 17–24. doi: http://doi.org/10.1016/j.blre.2014.09.003
  18. Jin, R., Krasinskas, A., Le, N.-A., Konomi, J. V., Holzberg, J., Romero, R., Vos, M. B. (2016). Association between plasminogen activator inhibitor-1 and severity of liver injury and cardiovascular risk in children with non-alcoholic fatty liver disease. Pediatric Obesity, 13 (1), 23–29. doi: http://doi.org/10.1111/ijpo.12183

Downloads

Published

2018-11-27

How to Cite

Bazhenova, N. (2018). State of anticoagulant and fibrinolytic systems of blood in patients with hypertension in combination with non-alcoholic fatty liver disease. ScienceRise: Medical Science, (7 (27), 14–18. https://doi.org/10.15587/2519-4798.2018.147805

Issue

No. 7 (27) (2018)

Section

Medical Science

License

Copyright (c) 2018 Bazhenova Nataliia

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.